Lexicon Pharmaceuticals, Inc. filings document a biopharmaceutical issuer with common stock listed on The Nasdaq Capital Market under LXRX. Its regulatory record includes Form 8-K reports on operating and financial results, clinical and regulatory updates, material agreements, debt financing, equity offerings and conversions of preferred stock into common stock.
Proxy and governance filings describe director elections, executive compensation, equity incentive plans and shareholder voting matters. Registration and prospectus-related disclosures address common-stock issuance programs, capital structure and public-market financing alongside the company's development programs in cardiometabolic and neurologic disease areas.
LEXICON PHARMACEUTICALS, INC. senior vice president Rachel Yap Martens reported equity compensation activity involving restricted stock units and common shares. On February 28, 2026, she exercised 67,090 restricted stock units, converting them into 67,090 shares of common stock at a price of $0.00 per share.
In a related tax event on the same date, 35,826 common shares were disposed of at $1.47 per share to satisfy tax withholding obligations, as described in the footnotes. After these transactions, she held 31,264 shares of common stock and 134,180 restricted stock units directly. Each restricted stock unit represents the right to receive one share of common stock and vests in three equal annual installments each February 28 following the grant year.
LEXICON PHARMACEUTICALS, INC. Senior Vice President and Chief Medical Officer Craig B. Granowitz reported multiple equity award transactions involving restricted stock units and common stock on February 28, 2026.
He exercised or converted restricted stock units into common shares in three separate transactions of 35,790, 74,226, and 202,260 restricted stock units, each at a stated price of $0.00 per unit. Each restricted stock unit represents a contingent right to receive one share of common stock, and these units vest in three equal annual installments on February 28 of each of the three years following the year of grant.
Corresponding non-derivative entries show acquisitions of common stock in matching amounts of 35,790, 74,226, and 202,260 shares, reflecting the settlement of those restricted stock units. A separate transaction disposed of 109,098 shares of common stock at $1.47 per share through withholding of a portion of the issued shares by the company to satisfy the reporting person’s tax withholding obligations. After these transactions, the reporting person directly owned 323,430 shares of common stock.
LEXICON PHARMACEUTICALS, INC. senior vice president of Discovery, Suma Gopinathan, reported multiple equity compensation transactions. On February 28, 2026, she acquired common stock through the exercise and conversion of restricted stock units in blocks of 14,000, 20,310 and 65,640 shares, each at a conversion price of $0.0000 per share. A separate transaction disposed of 24,338 shares of common stock at $1.4700 per share to cover tax withholding obligations, leaving her with 150,132 directly held common shares.
LEXICON PHARMACEUTICALS, INC. senior vice president Lisa DeFrancesco reported equity award activity on common stock. On February 28, 2026, she acquired shares through the exercise and conversion of restricted stock units, including 24,674 and 128,190 units, each representing a right to one common share. A separate transaction disposed of 74,572 common shares at $1.47 per share to satisfy tax withholding obligations, leaving her with directly owned common shares as reported in the filing.
LEXICON PHARMACEUTICALS SVP and General Counsel Brian T. Crum reported multiple exercises of restricted stock units into common stock on February 28, 2026. These were non-cash conversions at $0.00 per share, increasing his directly held common shares. The company also withheld 105,019 common shares at $1.47 per share to cover tax obligations related to the equity awards.
Lexicon Pharmaceuticals SVP & CFO Scott M. Coiante reported equity award activity. On February 28, he acquired 160,237 shares of common stock through the exercise of restricted stock units at no cost, while 54,881 shares were withheld by the company to cover tax obligations. Following these transactions, he directly owns 105,356 shares of common stock and 320,473 restricted stock units, each representing the right to receive one share as they vest over time.
LEXICON PHARMACEUTICALS, INC. Chief Executive Officer Michael Exton reported equity award activity involving restricted stock units and common stock on February 28, 2026. He exercised or converted 503,263 restricted stock units, receiving an equivalent number of common shares at a stated price of $0.00 per share.
In a related tax-withholding disposition, 204,831 common shares were withheld by the company at $1.47 per share to satisfy withholding obligations. Following these transactions, Exton directly held 1,006,527 restricted stock units and 298,432 common shares. The footnotes clarify that each restricted stock unit converts into one share and that vesting occurs in three equal annual installments after grant.
LEXICON PHARMACEUTICALS director Raymond Debbane reported an open-market purchase of company stock. He bought 2,000 shares of common stock at a price of $1.49 per share, bringing his directly held stake to 1,906,186 shares.
The filing also lists indirect holdings in Lexicon Pharmaceuticals common stock through various affiliated investment entities, including 1,538,462 shares held by Avicenna Life Sci Master Fund LP and related parties, 7,362,368 shares by Invus Public Equities, L.P. and related parties, 5,451,204 shares by Invus US Partners, LLC and related parties, and 35,402,689 shares by Invus, L.P. and related parties.
Lexicon Pharmaceuticals director Raymond Debbane reported an open-market purchase of 100,000 shares of common stock at $1.47 per share. Following this buy, he directly holds 1,904,186 shares. The filing also lists additional indirect holdings through Avicenna Life Sci Master Fund LP and several Invus investment entities.
Lexicon Pharmaceuticals director Raymond Debbane reported buying 150,000 shares of common stock in open-market transactions. On February 19, he purchased 50,000 shares at a weighted average price of $1.4393 per share, and on February 20 he bought 100,000 shares at a weighted average price of $1.4779 per share.
After these purchases, his directly owned stake increased to 1,804,186 common shares. The filing also reports additional common stock positions as indirectly owned through entities including Avicenna Life Sci Master Fund LP, Invus Public Equities, L.P., Invus US Partners, LLC, and Invus, L.P.